- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Approvals, Patient Selection, and SC Amivantamab
Panelists discuss how recent FDA approvals and SC amivantamab data support broader use of subcutaneous therapy in NSCLC.
EP: 1.Understanding EGFR Mutations and First-Line Treatment
EP: 2.Overcoming Resistance Mechanisms and Addressing Unmet Needs
EP: 3.Impact of Recent Approvals and Novel Mechanisms
EP: 4.CNS Penetration and Efficacy of Emerging Therapies
EP: 5.Managing Adverse Events and Integrating Amivantamab Plus Lazertinib
EP: 6.Sequencing Therapies and Using the Most Effective Options First
EP: 7.The Value of Subcutaneous Therapy for Patients
EP: 8.FDA Approvals, Patient Selection, and SC Amivantamab
Panelists discuss how recent FDA approvals for subcutaneous (SC) oncology agents are expanding therapeutic flexibility. They highlight approvals for SC versions of atezolizumab, nivolumab, and pembrolizumab, as well as clinical data from the PALOMA trials evaluating SC amivantamab. The discussion reviews findings demonstrating equivalent efficacy, safety, and pharmacokinetics to intravenous (IV) formulations. Panelists also address patient selection criteria, clinical considerations for integrating SC therapies with IV regimens, and how these innovations enhance workflow efficiency and patient experience.
Brensocatib Improves Outcomes in Non-Cystic Fibrosis Bronchiectasis With or Without Comorbid COPD
November 8th 2025Brensocatib improves lung structure and reduces exacerbations in non-cystic fibrosis bronchiectasis with or without COPD, according to posters presented at this year's CHEST meeting.
Read More
